Ascletis Pharma Inc.

Investors

2025

2024

2023

2022

2021

2020

2019

2018

Voluntary Announcement - Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight
2025-08-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025
2025-08-04
Voluntary Announcement - Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-Week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30
2025-07-28
Notice of Board Meeting
2025-07-21
Voluntary Announcement - Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
2025-07-15
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
2025-07-04
Voluntary Announcement - Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-Week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
2025-07-03
Voluntary Announcement - Business Update: Third-Party Petition Filed against the Company’s U.S. Patent
2025-06-30
Nomination Committee - Terms of Reference
2025-06-27
Voluntary Announcement - Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis
2025-06-18

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1